Tezosentan is a non-selective ET_A and ET_B receptor antagonist. It acts as a vasodilator and was designed by

Actelion Actelion is a pharmaceuticals and biotechnology company established in December 1997, headquartered in Allschwil near Basel, Switzerland. Actelion focuses on the manufacture of drugs that treat rare diseases and orphan diseases. Some of the dru ...

as a therapy for patients with acute

heart failure Heart failure (HF), also known as congestive heart failure (CHF), is a syndrome, a group of signs and symptoms caused by an impairment of the heart's blood pumping function. Symptoms typically include shortness of breath, excessive fatigue, ...

. However, studies showed that tezosentan did not improve

dyspnea Shortness of breath (SOB), also medically known as dyspnea (in AmE) or dyspnoea (in BrE), is an uncomfortable feeling of not being able to breathe well enough. The American Thoracic Society defines it as "a subjective experience of breathing disc ...

or reduce the risk of fatal or nonfatal cardiovascular events.

References

Vasodilators Tetrazoles Pyridines Pyrimidines Phenol ethers Sulfonamides Alcohols Endothelin receptor antagonists Isopropyl compounds Diaryl ethers {{cardiovascular-drug-stub